Analysts expect a consensus revenue of $5.39 million and a net loss of $0.16 per share, with the stock trading at $0.99 versus a $4.00 average price target. Investors are primarily focused on the company’s liquidity and potential 'going concern' risk after management flagged a significant cash crunch in preliminary updates.
Nano X recently withdrew its 2026 annual guidance due to longer-than-expected commercialization cycles and initiated a headcount reduction to preserve capital. This report is critical for demonstrating progress in teleradiology service revenue and confirming the ramp-up of Nanox.ARC system deployments for the second half of the year.